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ABSTRACT
The term “mastocytosis” denotes a heteroge-
neous group of disorders characterised by abnormal
growth and accumulation of mast cells (MC) in one
or more organ systems. Symptoms result from MC
chemical mediator’s release, pathologic infiltration of
neoplastic MC in tissues or both. Multiple molecular,
genetic and chromosomal defects seem to con-
tribute to an autonomous growth, but somatic c-kit
D816V mutation is more frequently encountered, es-
pecially in systemic disease.
We present a literature review of mastocytosis
and a rare case report of an 18 month-old-girl with a
bullous dermatosis, respiratory distress and anaphy-
laxis, as clinical manifestations of mastocytosis.
The developments of accepted classification sys-
tems and novel useful markers allowed a re-evalua-
tion and updating of the classification of mastocyto-
sis. In paediatric age cutaneous forms of disease
prevail and may regress spontaneously. SM is more
frequently diagnosed in adults and is a persistent
(clonal) disease of bone marrow. The clinical course
in these patients is variable.
Today diagnostic criteria for each disease variant are
reasonably well defined. There are, however, peculiar-
ities, namely in paediatric age, that makes the diagnos-
tic approach difficult. Systemic disease may pose dif-
ferential diagnostic problems resulting from multiple
organ systems involvement. Coversly, the “unex-
plained” appearance of those symptoms with no skin
lesions should raise the suspicion of MC disease.
This case is reported in order to stress the clinical
severity and difficult diagnostic approach that paedi-
atric mastocytosis may assume.
Key words: Mast cell. Mastocytosis. Classification.
Criteria. Diagnosis. Childhood. Anaphylaxis. Review.
INTRODUCTION
In 1869, Nettleship and Tay first described the typ-
ical mastocytosis lesions (urticaria pigmentosa) as a
rare form of urticaria.1 Soon after the discovery of
mast cells (MC), by Paul Ehrlich in 1879, these le-
sions were found to contain focal accumulations of
MC.2 However, it was not until 1949 that Ellis de-
scribed the systemic variant of the disease with in-
volvement of visceral organs.3
DEFINITION
The term “mastocytosis” denotes a heteroge-
neous group of disorders characterised by abnormal
growth and accumulation of MC in one or more or-
gan systems. It is also described as a neoplastic dis-
ease involving MC and their progenitors CD34+.4
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EPIDEMIOLOGY
Current estimates on prevalence of mastocytosis
range from 1 in 1000 to 8000 patients in the derma-
tology office.5 In children approximately 5.4 cases per
1000 children are treated in dermatological clin-
ics.6 Rosbotham et al estimated that there are two
new cases per year in a population of 300,000 corre-
sponding to an incidence of 0.000667 %.7
Mastocytosis occurs equally in both sexes and as
been described in different ethnic groups, although
there are more reports in caucasians.8
PATHOPHYSIOLOGY
MC are haematopoietic cells that reside in vascu-
larized tissues, namely the connective tissues, often
in the vicinity of smaller or larger blood vessels or
nerve fibres.9,10 They are derived from multipotent
hematopoietic progenitors CD34+, detectable in
bone marrow as well as peripheral blood. Subse-
quently they distribute in the blood and transmigrate
through the endothelial barrier into tissues before un-
dergoing terminal differentiation and maturation.11,12
During differentiation MC acquire distinct morpho-
logic and phenotypic properties with four defined
stages of maturation: the non-granulated (tryptase-
positive) blast cell; the metachromatic blast cell; the
promastocyte/atypical MC type II and the mature
MC.13 Several cytokines and the local microenviron-
ment are considered to contribute to mastopoiesis.
A pivotal cytokine in this process, the principle MC
growth factor, is the Stem Cell (SCF) or kit-ligand.14-18
The effects of SCF on MC and their progenitors are
mediated through a specific MC’s receptor – trans-
membrane tyrosine kinase receptor, KIT or CD117.12
This is in turn encoded by the c-kit proto-onco-
gene.12,19 Therefore, a “gain-of-function mutations”
in the c-kit gene might be associated to enhanced
growth and resistance to apoptosis of MC and their
progenitors.20 Several c-kit mutations have been
identified.10 The point mutation D816V (Asp-816-Val)
is the most frequently detected (> 80 % of all pa-
tients with SM).21-24 Apparently additional defects
are needed (molecular, genetic and chromosomal) in
order for an autonomous cellular growth to occur.25-27
In contrast to sporadic cases, patients with familial
Mastocytosis usually fail to express c-kit mutations,22
associated with resistance to imatinib.28 Yet, a novel
c-kit mutation has been identified in familial respon-
sive to imatinib therapy.27 The heterogeneity of c-kit
mutations, and consequent clinical heterogeneity
(age of onset of disease, patterns of skin disease, de-
gree of organic involvement, hematopathology, me-
diator levels, response to therapy and prognosis),
makes genotype-phenotype correlations characteri-
zation difficult.29,30 At least four ways have been sug-
gested: single mutation at codon 816; sequential mu-
tations (mutation at codon 816 allows further
mutations); simultaneous mutations (others than
816 mutation) and chromosomal instability (predis-
posing to mutation at codon 816 and others).29
Another important pathogenic aspect (in SM) is
the abnormal expression of cell surface adhesion
antigens CD2 (LFA-2) and CD25, identified by multi-
coloured flow cytometry.31,32 The most immature MC
progenitors (both normal and neoplastic) express
CD13, CD34 and CD117.
MC are easily recognisable by their metachromat-
ic intracytoplasmatic granules where vasoactive and
immunoregulatory mediators including histamine,
heparin and cytokines are stored. Several are re-
leased in response to aggregation of the high affinity
IgE receptor, activation through complement recep-
tors or activation by cytokines.12 Others, such as
tryptase, are both constitutively secreted from MC
and released after its activation. Two tryptase genes
( and ) are expressed by human MC. -(pro) tryp-
tase is secreted constantly from the cell and its
levels reflect the total tryptase baseline, which
appear to correlate with the MC number.33 -tryptase
is stored in MC granules and levels are found to be
elevated after MC activation, such as anaphylaxis,
and are usually otherwise undetectable. Total serum
tryptase levels are a reliable non-invasive diagnostic
approach to estimate the burden of MC in patients
with mastocytosis and allow the distinction between
categories of disease.34 In healthy individuals an
average 5ng/ml is found (< 15 ng/ml).33
Symptoms in mastocytosis result from MC-derived
mediators and, less frequently, from destructive infil-
tration of MC [skin, bone marrow, gastrointestinal
tract, skeletal, central nervous system (CNS) or lym-
phoreticular system (spleen, liver and lymph nodes)].37
The MC produce and release a variety of clinically rel-
evant mediators such as histamine, leukotrienes, pro-
teases or heparin (table I). Depending on the type of
MC involved, burden of MC, course of disease and
co-existing disorders, these mediators may be released
to a variable degree resulting in different clinical pat-
terns.38-40 In some of these patients the symptoms are
mild and may not require therapy, in others, they are se-
vere and potentially fatal (urticaria, recurrent flushing,
dyspnoea, chest pain, bleeding tendency, peptic ulcer,
abdominal pain, severe bone pain, headache, recurrent
syncope and hypotensive shock).38-40
Organ infiltration may occur: without organ dys-
function (B-findings); with impaired organ function
(C-findings) or organ failure (table II).
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CLASSIFICATION
On the basis of recent advances in mastocytosis
research, an updated consensus classification for
mastocytosis was proposed in 2001 and subse-
quently adopted by the WHO (table III).41
The proposed classification is based on formulated
criteria. In this concept cutaneous mastocytosis (CM)
is based on clinical (urticaria pigmentosa, Darier’s
sign, mastocytoma) and histological findings (multi/
focal or diffuse infiltrates of MC) together with the
absence of criteria that would allow the diagnosis of
SM. SM criteria are divided into major criteria (histo-
logical and immunohistochemical) and minor criteria
(typical cytomorphological and novel biochemical
markers) listed in table IV.
The existence of one major and one minor criteri-
on or three minor criteria establish the diagnosis of
SM.41
CLINICAL FEATURES
The occurrence of mastocytosis is usually spo-
radic. Familial mastocytosis (AD) is a very rare condi-
tion with only 50 families recorded in the literature
since 1880.22 In up to 15 % of patients the disease is
congenital.35
Approximately 65 % of individuals with mastocy-
tosis present with disease in childhood; 55 % of
these have manifestations of disease by the age of
two. The remaining 35% that develop the symptoms
after puberty are classified as adult onset.36
Most pediatric cases of mastocytosis are asymp-
tomatic or minimally symptomatic with spontaneous
resolution during or after adolescence (50 %).42
Around 90 % of these patients have isolated cuta-
neous symptoms, while 10 % have systemic in-
volvement.43 It is, therefore, a benign condition.44
Urticaria pigmentosa (UP) is the most common
variant of CM.45 It usually presents as red-brown
macules and papules, often with symmetrical distrib-
ution and even anaphylactic reaction after mechani-
cal/thermal stimulation of skin lesions.46 In contrast,
dermographism is characterised by the appearance
of the same lesions after stroking or scratching nor-
mal appearing skin. Three rare subvariants of UP
have been proposed based on distinct clinical as-
pects: plaque form, a nodular form and a telangiecta-
sic (Telangiectasia Macularis Eruptiva Persistans –
TMEP). The younger the patient and the smaller the
number of the lesions the higher the probability of
spontaneous remission. An adult onset of disease
raises the risk of systemic involvement and long per-
sistence.10 Bullous mastocytosis or Diffuse CM is a
very rare and severe variant of CM which usually oc-
curs in the first year of life.47 It is characterised by in-
tensely itchy, generalised yellowish, thickened skin
with doughy/leathery feel and the appearance of
large blisters, sometimes haemorrhagic, sponta-
neously or following mild trauma due to diffuse MC
infiltration.45,47 Children with more extensive skin in-
volvement are more likely to exhibit systemic symp-
toms: flushing, headache, palpitations, abdominal
pain, diarrhoea, dyspnoea, wheezing, syncope, hy-
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Table I




Vascular instability Histamine, cysLT, PGD2, PAF
Increased vasopermeability Histamine, cysLT, PGD2, PAF
Fibrosis TGF-
Eosinophilia IL-5








Urticaria Histamine, LTC4, PAF
Lungs
Bronchoconstriction Histamine, cysLT, PGD2, PAF, 
endothelin
Secretion of mucus Histamine, LTC4, PGD2
Pulmonar oedema Histamine, cysLT, PAF
Gastrointestinal Tract
Gastric Hypersecretion Histamine
Cramping, abdominal pain Histamine, cysLT, PAF
Diarrhoea Histamine
Skeletal System




Headache, mood and 
cognitive changes Histamine, PGD2
LT, leukotrienes; PG, prostaglandins; PAF, Platelet Activating Factor; 
TGF, Transforming Growth Factor; IL, interleukin; SCF, Stem Cell Factor; 
TNF, Tumor Necrosis Factor; TPA, Tissue Type Plasminogen Activator; 
CNS, Central Nervous System.
Adapted from Valent et al.5
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Table II
B and C findings
B-findings C-findings* Organ failure
b.m: bone marrow; ANC: absolute neutrophile count; Plt: platelets; LN: lymph node; US: ultrasound; CT: computer tomography.
*C-findings: impaired organ function due to infiltration by neoplastic MC.
Adapted from Valent et al.5
1) High MC burden:
Infiltration grade MC of b.m. > 30 %
(histology) and serum
tryptase > 200 ng/ml
2) Dysmyelopoiesis: 
hypercellular marrow; loss of fat cells;
myelodysplasia or myeloproliferative;




without ascitis or 
other signs of organ impairment 
and/or 
lymphadenopathy [palpable or 
visceral LN enlargement found in US 




1) Organopathy (b.m.) 
Cytopenia/s: 
ANC < 1000/l 
Hb < 10 g/dl 
Plt < 100000/l
2) Organopathy (liver) palpable hepathomegaly 
with ascitis, abnormal liver function and/or 
portal hypertension 
3) Organopathy (spleen) palpable + hypersplenism
4) Organopathy (Gastrointestinal tract)
malabsorption + hypalbuminemia + weight loss
5) Organopathy (skeletal) 
bone lesions with large osteolisis 
and/or 
Severe osteoporosis + pathologic fractures
Severe progressive pancytopenia 
ANC < 1000/l 
Transfusion dependence
Plt < 20 000/l
Progressive deterioration





WHO classification of Mastocytosis
Variants and subvariants Abbreviation
Cutaneous Mastocytosis CM
Maculopapular CMa MPCM/UP
Diffuse or Bullous CM DCM
Cutaneous Mastocytoma
Indolent Systemic Mastocytosis ISM
Smouldering SM
Isolated bone marrow Mastocytosis BMM
Systemic Mastocytosis with an Associated 
clonal haematologic non-MC lineage disease SM-AHNMDb
Aggressive Systemic Mastocytosis 





aalso termed urticaria pigmentosa.
bthe subtype of AHNMD has to be defined by WHO criteria as well.
cin a sub-group of these patients, FIP1L1-PDGFRA fusion gene is detectable.
din these patients circulating MC are less than 10 %.
Adapted from Valent et al.5
potensive shock and death.45 Early onset of blisters
worsens the prognosis. It is also associated with an
increased risk of progression to MCL.48 The masto-
cytoma of the skin presents as a macular, papular or
nodular (< 1cm) lesion of yellow, brown or reddish
colour. It rarely evolves into SM-AHNM.49
Patients with adult onset mastocytosis generally
have evidence of systemic disease (SM). It can fol-
low a benign/indolent course as a persistent clonal
disorder (disorder of the bone marrow) or it may be
associated with life-threatening haematologic disor-
ders. SM includes four major subtypes: indolent SM
(ISM); SM associated with non-mast cell clonal
haematological disease (SM-AHNMD); aggressive
SM (ASM); and MC Leukemia (MCL).41 ISM repre-
sents 2/3 of all cases of SM and shows a prolonged
clinical course (survival time of two decades or
more).41 SM-AHNMD combines two completely dif-
ferent histologies: the MC lineage and non-MC lin-
eage (myelodysplastic syndrome, myeloproliferative
syndrome, acute myeloid leukemia, Non-Hodgkin’s
lymphoma). The haematological disease associated
is most frequently (80-90 %) of myeloid lineage.41
The type of haematologic disorder associated deter-
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mines its prognosis. It is, therefore, important to ac-
curately determine the type of SM in these pa-
tients.41 ASM is characterised by progressive infil-
tration of various organs with function impairment
(severe cytopenias, malabsorption, bone fractures,
peripheral eosinophilia, and hepatopathy) but usually
without typical skin lesions.41 The clinical course is
variable. MCL is characterized by leukemic infiltra-
tion of various organs by immature neoplastic MC.
The prognosis is often poor.41 Localised MC prolifer-
ations are extremely rare and include both Extracu-
taneous Mastocytoma and MC Sarcoma.41 Masto-
cytoma is a benign tumour with uniformal growth,
low grade cytology and good prognosis.41 MC Sarco-
ma is a local destructive tumour, usually with poor
prognosis.41
Patients with SM should be followed-up to moni-
tor the development of any signs of disease progres-
sion or evolution to AHNMD.
DIAGNOSTIC EVALUATION
Current available diagnostic and staging methods
are listed in table V.
Patient’s age, clinical findings and laboratory para-
meters determine the choice of diagnostic and stag-
ing methods.
In paediatric patients the disease is usually re-
stricted to the skin and bone marrow examination is
not required unless there is late presentation of skin
lesions (> 5 years),50 organomegaly, significant pe-
ripheral blood abnormalities or persistently elevated
serum tryptase levels (> 20 ng/ml).41,51 In early child-
hood slightly raised serum tryptase levels might be
related with a different ratio of MC granule volume/
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Table IV
Proposed criteria to diagnose mastocytosis
Cutaneous mastocytosis: Typical skin lesions = typical clinical signs (UP/MCMP, MCD, mastocytoma)
+
positive histology with typical infiltrates of MC (diagnostic infiltrate pattern: multi/focal or diffuse)
Systemic mastocytosis: «SM Criteria»
Major: Multifocal dense infiltrates of MC (> 15 MC aggregating) detected in sections of bone marrow and/or other extracutaneous organ(s) or by
tryptase-immunochemistry or other stains
Minor: a) in bone marrow or other extracutaneous organs MC infiltrates, > 25 % of MC are spindle-shaped/atypical MC (type I and type II) of the
bone marrow comprise > 25 % of all MC
b) detection of c-kit mutation D816V in bone marrow, blood
c) KIT+ MC in bone marrow, blood or extracutaneous organs co-express CD2 or/and CD25
d) serum total tryptase concentrations persistently > 20 ng/ml (not valid in AHNMD)*
If 1 Major criteria + 1 Minor criteria or 3 Minor criteria = diagnosis of Systemic Mastocytosis
*In myelodysplasic/myeloproliferative syndromes and acute myeloid leukemia elevated serum tryptase levels have been detected without an increase 
in MC number or signs of mastocytosis.
Adapted from Valent et al.5
Table V
Diagnostic and Staging methods of Mastocytosis
General Evaluation






(Consider Hymenopter venom’s specific IgE if SM)
Diagnostic Evaluation
Serum tryptase
Skin examination: macroscopic and microscopic (skin biopsy)
Bone marrow aspirate and biopsy:
– Recommended stains: Giemsa, Toluidine Blue; Anti-tryptase;




– Cell number and morphology
– b.m. tryptase level
Research of somatic c-kit mutation (codon 816 and others)





GI endoscopy (with biopsy)
EEG/Neuropsychiatric Evaluation
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total body volume and total volume of skin MC/to-
tal body volume, compared with adults.28
Therefore, consideration should be given to moni-
toring the serum tryptase level over time and to not
perform a bone marrow punction unless there are
suggesting signs of systemic disease.
The existence of more then 15 MC per aggregate
(diffuse or multifocal infiltrates with a significant per-
centage of spindle-shape cells) fulfils the diagnosis of
SM.52 If the majority of MC are round it is necessary
to investigate additional criteria because such accu-
mulations have been detected in reactive MC hyper-
plasia (parasite infections neoplastic disorders, aplas-
tic anemia, and chronic inflammatory diseases),
SCF-treated patients and myeloid leukemia without
mastocytosis.41
We present a practical guide for diagnostic work-
up in patients with suspected mastocytosis in
table VI. Figure 1 shows a diagnostic algorithm dis-
criminating mastocytosis variants.
DIFFERENTIAL DIAGNOSIS
SM symptoms, in the absence of skin lesions, are
often non-specific and thus confused with other un-
derlying conditions namely: endocrine (adrenal tu-
mour, gastrinoma, VIPoma, carcinoid syndrome), car-
diovascular (idiopathic anaphylaxis, cardiac disease,
aortic stenosis, vasculitis, essential hypertension),
gastrointestinal (peptic ulcer, ulcerative colitis, he-
patitis, parasite disease, gluten-sensitive enteropa-
thy), pulmonary, allergic, infectious, immunologic,
rheumatologic and oncologic.41,10
However, one should be alert to the possibility of
MC disease when patients present “inexplicable”
symptoms that might be related with MC-mediator
release such as vascular instability, anaphylactic
shock, flushing, diarrhoea and headache, even if no
skin lesions are found.
TREATMENT
It is consensual, since no curative therapies are
available, that mastocytosis should be treated ac-
cording to the symptoms presented.53,54
In patients with predominant mediator-release
symptoms, “mediator-targeting” drugs must be pre-
scribed in addition to avoidance of triggers of MC de-
granulation53,54 (table VII).
Commonly used medication includes anti-hista-
mines (H1/H2), MC stabilisers, acetylsalicylic acid
(aspirin), ketotifen or adrenaline. Aspirin is used for
flushing, tachycardia and syncope.55 Ketotifen has
been recommended for bone pain and/or flush-
ing.56,57 Gastric ulcerative disease requires the use of
H2 anti-histamines or a proton pump inhibitor.56 In
Allergol et Immunopathol 2008;36(3):154-63
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Table VI
Practical guide for diagnostic work-up in patients with suspected mastocytosis
Initial sign/symptom Recommended diagnostic procedures
UP-like skin lesions (paediatric patients) 1. Skin biopsy (with analysis of c-kit D816V) + serum tryptase (monitoring)a
2. Bone marrow investigation in cases with suspected hematologic disease/SM
UP-like skin lesions (adult patients) 1. Bone marrow examination + skin biopsy + serum tryptase (> 20 ng/ml in most cases)
2. In case of MS – complete stagingb
Reported mediator symptoms 1. Serum tryptase, if > 20 ng/ml – 2
but no skin lesions (UP) 2 2. Bone marrow examination, if SM – 3
3. SM – stagingc
Severe unexplained allergic reaction/ 1. Serum tryptase, if > 20 ng/ml – 2
Anaphylaxis at presentation 2. Repeat serum tryptase a few weeks later, if serum tryptase > 20 ng/ml – 3
3. bone marrow examination, if SM – 4
4. SM-stagingc
aIn young infants, a serum tryptase slightly exceeding 20 ng/ml is not regarded as a safe indicator for SM. Therefore, it is recommended to wait and to monitor
the serum tryptase level over time in these patients.
bComplete staging: gastrointestinal tract, skeleton (X-ray, scintigraphy), abdomen US, complete blood count, serum chemistry, coagulation, c-kit mutations.
cEspecially in patients with aggressive MC disorders, skin lesions are absent. Therefore, it is of pivotal importance to know the subtype of SM in these patients 
as soon as possible. In ASM serum tryptase level is usually higher than in patients with isolated bone marrow mastocytosis (often < 20 ng/ml), a benign MC
disease in which skin lesions are also absent.
Adapted from Valent et al.6
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many patients a combination of H1 and H2 anti-hist-
amines is administered. Low dose of corticosteroids
may relieve malabsorption and ascitis.56 Self adminis-
tered epinephrine is indicated in recurrent anaphylac-
Allergol et Immunopathol 2008;36(3):154-63
Silva I et al.—MASTOCYTOSIS: A RARE CASE OF ANAPHYLAXIS IN PAEDIATRIC AGE AND LITERATURE REVIEW160
Suspected MC-Disease
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tic episodes.53,54 Specific immunotherapy for hy-
menoptera venom might be considered in patients
with SM.58 Cutaneous lesions may show good (tran-
sient) response to Psoralen-PhotoChemotherapy
(PUVA)59 or local corticosteroids.
In case of rapid or aggressive disease progression
cytoreductive drugs are recommended: -interferon,
with or without corticosteroids, or cladribine.54,55 If no
benefit is achieved one should consider experimental
poly-chemotherapy or bone marrow transplant
(haematopoietic stem cells).28 Although these modal-
ities can render significant MC reduction and symp-
tom control in some patients, responses are tran-
sient and the prognosis remains unchanged.51
In patients with significant splenomegaly and hy-
persplenism, splenectomy may be considered.60
Surgical excision and consecutive radiation and/or
high-dose chemotherapy should be considered in pa-
tients with MC sarcoma.
Future strategies are presently focused on the
identification of molecular/genetic markers and po-
tential drug targets in neoplastic MC. Investigation is
addressed to targeted-drugs such as: tyrosine kinase
inhibitors (imatinib mesilate, AMN107, desatinib,
PKC412), non tyrosine kinase kit signalling inhibitors
(geldanamycine, bortezomib, rapamycin) and mono-
clonal antibodies (denileukine diftitox, gemtuzumab
ozogamicin).61 O imatinib mesilate is currently the
only such drug approved by the Food and Drug Ad-
ministration (FDA) that might be useful in SM (ASM)
associated to gene defects such the FIP1L1-PDGFRA
fusion gene62,63 and others (excluding the c-kit muta-
tion of D816V).64
Preliminary data of a study conducted by Carter et
al demonstrates that anti-IgE therapy (omalizumab)
may have efficacy in preventing anaphylaxis in pa-
tients with SM resulting from reduction of MC sur-
vival and overaccumulation.65
CASE REPORT
We present a case report of an 18 month-year-old,
caucasian girl. She had a dystocic birth at 37 weeks
and neonatal hypoxic-ischemic encephalopathy with
hypotension. She is a child of non-consaguineal par-
ents and with maternal history of atopic dermatitis
and latex allergy.
At four months of age the child exhibited a prurig-
inous microvesicular rash of the neck. It was diag-
nosed as atopic dermatitis and treated accordingly.
However, there was a progressive worsening, show-
ing extension of skin lesions to the trunk. Six months
later she developed an erythematous rash of the
face and trunk followed by respiratory distress and
respiratory arrest and syncope. The child’s mother
gave her a cold bath with immediate recovery. She
was treated with intravenous corticosteroid and oral
anti-histamine in the emergency department. Appar-
ently there was no prior episode of fever, cold symp-
toms, insect stings, trauma, sudden/intense tem-
perature changes or histamine-release food/drink
ingestion. Less than 24 hours after hospital dis-
charge, a bullous dermatosis with transparent fluid of
the face, neck and trunk started along with dysp-
noea. She was taken to the hospital and remained
admitted for 2 weeks, showing total remission under
treatment with adrenaline, oral and topical corticos-
teroids, hydroxizine, ketotifen and flucloxaciline. The
skin biopsy confirmed the diagnosis of mastocytosis.
Laboratory work-up showed raised levels of
serum tryptase (381 ng/ml) and total IgE (1138 KU/L).
Complete blood cell count, peripheral blood smear,
serum biochemistry, skeletal X-ray, and abdominal ul-
trasound were all normal. Posterior evaluation
showed a significant reduction of serum tryptase lev-
el to 25ng/ml. The absence of persistent significant-
ly raised levels of serum tryptase, organomegalies
and skeletal or peripheral blood anomalies eliminated
the indication for bone marrow biopsy/puncture.
No further anaphylactic episodes occurred. How-
ever, daily episodes of flushing and urticaria elicited
by heat, pressure and friction are noticed even un-
der regular treatment with cetirizine, dissodic chro-
moglycate, ketotifen and avoidance of trigger fac-
tors of MC mediator-release.
There were no side effects of therapy nor a need
for use of self-administered epinephrine prescribed.
Physical examination revealed urticarial skin le-
sions in areas that suffered pressure, resulting from
child’s handling. The remaining skin had a normal as-
pect and texture.
The c-kit mutation research is in progress.
Allergol et Immunopathol 2008;36(3):154-63
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Table VII
Triggering factors that induce release of MC mediators 
in patients with mastocytosis
– Insect stings, venoms (hymenoptera, jellyfish, snake)
– Food (shellfish, hot or alcoholic beverages, spices, cheese)
– Drugs (opioids, dextran, radiocontrasts, adrenergic and cholinergic
receptor antagonists, AAS and NSADs, local anesthesics)
– Alcohol
– Mechanical irritation (friction, pressure)
– Emotional or physical stress (exercise)
– Sudden temperature changes, prolonged heat or cold
– Infection (viral, bacterial)
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CONCLUSIONS
During the last few years, major advances in mas-
tocytosis research have been made. Thus, by using
defined criteria it is now possible to discriminate be-
tween MC disorders and other systemic diseases.
Mastocytosis is a relatively rare disorder, but its di-
agnosis is of relevance because of the multiple clini-
cal manifestations and due to the risk of associated
symptoms.
Although pediatric mastocytosis is usually benign,
sometimes it can be clinically exuberant or severe
and with a difficult diagnostic approach. Multidisci-
plinary work is therefore essential in order to diag-
nose, treat and manage the disease.
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